Skip to content

Phase I Study of Alferon N Injection in Persons With Asymptomatic Human Immunodeficiency Virus (HIV) Infection

Phase I Study of Alferon N Injection in Persons With Asymptomatic Human Immunodeficiency Virus (HIV) Infection

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00002078
Enrollment
Unknown
Registered
2001-08-31
Start date
Unknown
Completion date
Unknown
Last updated
2005-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV Infections

Keywords

Drug Evaluation, Interferon-alpha

Brief summary

To determine the safety and tolerance of subcutaneous injections of natural interferon alpha (IFN) in asymptomatic HIV-positive persons and record its effects on the HIV virus in these individuals.

Interventions

Sponsors

Walter Reed Army Institute of Research (WRAIR)
CollaboratorFED
Henry M. Jackson Foundation for the Advancement of Military Medicine
CollaboratorOTHER
Purdue Frederick
Lead SponsorINDUSTRY

Study design

Primary purpose
TREATMENT

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Patients must have: * HIV-1 seropositivity. * CD4 count \> 400/mm3. * Eligibility for care in the military medical system. Prior Medication: Allowed: * Acyclovir.

Exclusion criteria

Co-existing Condition: Patients with the following symptoms or conditions are excluded: * AIDS- or ARC-defining condition (unexplained weight loss, fever, diarrhea, night sweats). * Evidence of AIDS dementia. * Chronic hepatitis with severe liver dysfunction. * Active gastrointestinal, renal, respiratory, endocrine, hematologic, cardiovascular, or psychiatric disorder that would limit ability to complete the study. * Hemophilia. * Co-existent disease likely to result in death within the next 2 years. * Known hypersensitivity to human interferon alpha. * Known anaphylactic hypersensitivity to mouse immunoglobulin (IgG), egg protein, or neomycin. Concurrent Medication: Excluded: * Any other concurrent experimental medications. Patients with the following prior conditions are excluded: * History of AIDS- or ARC-defining condition (unexplained weight loss, fever, diarrhea, night sweats). * Evidence of chronic hepatitis with severe liver dysfunction. Prior Medication: Excluded within 5 days prior to study entry: * Immunosuppressive agents. * Chemotherapy. * Steroids. Excluded within 45 days prior to study entry: * BCG vaccine. * Isoprinosine. * Other immune modulators. Excluded within 3 months prior to study entry: * Any form of interferon. * Antiviral therapy. * Immunoregulatory therapy (other than acyclovir). 1\. Active drug abuse (narcotic or alcohol abuse documented within the past 6 months). * Unlikely or unable to comply with the requirements of the protocol.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026